
27 Jun, 2023 Findings from Phase 1 Study of ALN-HSD Presented at EASL Congress 2023
We presented findings from a Phase 1 study of ALN-HSD, an investigational RNAi therapeutic, in healthy adults and patients with nonalcoholic steatohepatitis, at the European Association for the Study of the Liver (EASL) Congress 2023.